Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Hepatology. 2015 Mar 20;61(5):1591–1602. doi: 10.1002/hep.27665

Figure 6. Addition of anti-PD-1 antibody to sorafenib and CXCR4 inhibition increases the expression of biomarkers of T lymphocyte activation in HCC.

Figure 6

(A–C) PD-1 blockade combined with sorafenib and AMD3100 induces a significant increase of T lymphocyte activation biomarkers IL-2 (A), TNF-α (B), and IFN-γ (C) in HCA-1 tumors versus HCCs in other treatment groups. Data are presented as mean±SEM (N =5 per group) *P<0.05.